Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2021-07-01 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Senzime AB (publ.) Pressreleaser Visa Stäng
2021-04-20 Senzime Senzime expands its commercial capability in the U.S Pressreleaser Ladda ner | Visa Stäng
2021-04-20 Senzime Senzime utökar sin kommersiella kapacitet i USA Pressreleaser Ladda ner | Visa Stäng
2021-04-19 Senzime Senzimes årsredovisning för 2020 Pressreleaser Ladda ner | Visa Stäng
2021-04-19 Senzime Senzime Annual Report 2020 Pressreleaser Ladda ner | Visa Stäng
2021-04-12 Senzime Kallelse till årsstämma i Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-04-12 Senzime Notice of annual general meeting in Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-05 Senzime Kommuniké från extra bolagsstämma i Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-05 Senzime Communique from extra general meeting in Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 5 Mar 2021 | Senzime

Communique from extra general meeting in Senzime AB (publ)

Election of new member of the Board of Directors

The extra general meeting resolved to elect Eva Walde as new member of the Board of Directors.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 708-13 34 17, e-mail: pia.renaudin@senzime.com

————

Uppsala 5  March 2021

Senzime AB (publ)

The board of directors

About SenzimeSenzime develops and markets systems, driven by unique algorithms and sensors, to follow patients’ nervous systems and electrical impulses – before, during and after surgery. The company’s solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company’s shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se,is Certified Adviser for Senzime. www.senzime.com

Communiqué from extra general meeting Senzime AB 2021-03-05 ( https://mb.cision.com/Public/11572/3301148/8fef880ec2e7896e.pdf )

2021-03-04 Senzime Senzime: TetraSens engångssensor erhåller rätt till subvention i Sydkorea Pressreleaser Ladda ner | Visa Stäng
2021-02-26 Senzime Senzime: Bokslutskommuniké 2020 Pressreleaser Ladda ner | Visa Stäng
2021-02-26 Senzime Senzime's Year-End Report 2020 Pressreleaser Ladda ner | Visa Stäng
2021-02-19 Senzime Kallelse till extra bolagsstämma i Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-02-19 Senzime Notice of extra general meeting in Senzime AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-02-15 Senzime Senzime har beslutat ansöka om notering av bolagets aktier på Nasdaq Stockholms huvudlista under 2021 Pressreleaser Ladda ner | Visa Stäng
2021-01-14 Senzime Senzime etablerar sig i Tyskland och får första order på TetraGraph-system Pressreleaser Ladda ner | Visa Stäng
2021-01-14 Senzime Senzime establishment and first TetraGraph-system order in Germany Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

31 Aug 2022 | Extrastämma 2022
10 Nov 2022 | Kvartalsrapport 2022-Q3